Reprint
Actinobacteria and Myxobacteria
Important Resources for Novel Antibiotics
Edited by
December 2020
271 pages
- ISBN978-3-03943-529-6 (Hardback)
- ISBN978-3-03943-530-2 (PDF)
This is a Reprint of the Special Issue Actinobacteria and Myxobacteria—Important Resources for Novel Antibiotics that was published in
Biology & Life Sciences
Environmental & Earth Sciences
Medicine & Pharmacology
Summary
Bacterial infections cause millions of deaths globally, particularly in children and the elderly, and four of the 10 leading causes of death are infectious diseases in low- and middle-income countries. The continuous use of antibiotics has resulted in multi-resistant bacterial strains all over the world, such as Community-associated Methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamases (ESBLs), and, as expected, hospitals have become breeding grounds for human-associated microorganisms, especially in critical care units.
Format
- Hardback
License and Copyright
© 2021 by the authors; CC BY-NC-ND license
Keywords
actinomycetes; antibiotic biosynthesis; silent biosynthetic pathways; γ-butyrolactones; HiTES; translation inhibitors; marine actinobacteria; Streptomyces sp.; enzyme inhibition; antimicrobial; antioxidant; cytotoxicity; GC-MS; pyrrolopyrazines; myxobacteria; antivirals; secondary metabolites; HIV; Ebola; hepatitis viruses; myxobacteria; diversity; uncultured; secondary metabolites; new antibiotics; Streptomyces; polyketides; secondary metabolite; polyketide synthases (PKSs)